Search Result

Results for "

AKT-IN-2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (15) Apoptosis (12) ASK1 (2) Autophagy (2) Bcl-2 Family (1) Beta-secretase (2) Caspase (1) Cholinesterase (ChE) (2) Interleukin Related (2) Keap1-Nrf2 (2) Ligands for Target Protein for PROTAC (1) MDM-2/p53 (3) Microtubule/Tubulin (1) MMP (1) mTOR (1) Organoid (2) PI3K (1) PKA (1) Prostaglandin Receptor (2) PROTACs (3) Reactive Oxygen Species (1) Ribosomal S6 Kinase (RSK) (1) ROCK (1) VEGFR (1)
By Research Areas:	Cancer (17) Inflammation/Immunology (3) Metabolic Disease (2) Neurological Disease (5)

By Targets:

Akt (15)

Apoptosis (12)

ASK1 (2)

Autophagy (2)

Bcl-2 Family (1)

Beta-secretase (2)

Caspase (1)

Cholinesterase (ChE) (2)

Interleukin Related (2)

Keap1-Nrf2 (2)

Ligands for Target Protein for PROTAC (1)

MDM-2/p53 (3)

Microtubule/Tubulin (1)

MMP (1)

mTOR (1)

Organoid (2)

PI3K (1)

PKA (1)

Prostaglandin Receptor (2)

PROTACs (3)

Reactive Oxygen Species (1)

Ribosomal S6 Kinase (RSK) (1)

ROCK (1)

VEGFR (1)

By Research Areas:

Cancer (17)

Inflammation/Immunology (3)

Metabolic Disease (2)

Neurological Disease (5)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Targets Recommended: Akt Dan family AIM2 NEKs

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-147768

PI3K/AKT-IN-2	PI3K Akt Microtubule/Tubulin MMP Apoptosis	Cancer
PI3K/AKT-IN-2 (Compound 12c) is a PI3K and AKT inhibitor. PI3K/AKT-IN-2 blocks the epithelial-mesenchymal transition (EMT) and induces apoptosis. PI3K/AKT-IN-2 inhibits the polymerization of tubulin .

HY-151613A

MS15 TFA	PROTACs Akt	Cancer
MS15 TFA is a potent and selective AKT PROTAC degrader. MS15 TFA inhibits the AKT1, -2, and -3 activities, with IC₅₀ values of 798 nM, 90 nM, and 544 nM, respectively .

HY-18749

SC79 Maximum Cited Publications 218 Publications Verification	Akt	Neurological Disease Inflammation/Immunology Cancer
SC79, a unique specific and BBB permeable Akt activator, activates Akt in the cytosol and inhibits Akt membrane translocation. SC79 specifically binds to the PH domain of Akt .

HY-N0314

Pectolinarin 2 Publications Verification	Interleukin Related Prostaglandin Receptor Apoptosis	Inflammation/Immunology
Pectolinarin possesses anti-inflammatory activity . Pectolinarin inhibits secretion of IL-6 and IL-8, as well as the production of *PGE2* and NO. Pectolinarin suppresses cell proliferation and inflammatory response and induces apoptosis via inactivation of the *PI3K/Akt* pathway .

HY-16071

AT13148 2 Publications Verification	Akt PKA ROCK Ribosomal S6 Kinase (RSK)	Cancer
AT13148 is an orally active and ATP-competitive, multi-AGC kinase inhibitor with IC₅₀s of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively.

HY-112148

*AKT-IN-2*	Akt	Cancer
AKT-IN-2 is a potent, selective and orally bioavailable AKT inhibitor with an IC₅₀ of 5 nM for AKT1 .

HY-169431

VEGFR-2/AKT-IN-2	VEGFR Akt Caspase Bcl-2 Family Apoptosis	Cancer
VEGFR-2/AKT-IN-2 (Compound 5) is a *VEGFR-2/AKT* inhibitor (IC₅₀: 0.061 μM for VEGFRin HepG2 cell). VEGFR-2/AKT-IN-2 reduces total and phosphorylated AKT as well as up-regulates BAX and Caspase-3 and down-regulates *Bcl-2* in cells, thereby promoting Apoptosis. VEGFR-2/AKT-IN-2 causes cell cycle arrest in S phase. VEGFR-2/AKT-IN-2 inhibits the growth of human liver tumor cells .

HY-48682

*AKT ligand-2*	Ligands for Target Protein for PROTAC	Cancer
AKT ligand-2 (compound 5) is an AKT ligand. AKT ligand-2 can be combined with VHL ligand (S,R,S)-AHPC (HY-125845) through linker to synthesize PROTAC MS21 (HY-141807) .

HY-151613

MS15	PROTACs Akt	Cancer
MS15 is a potent and selective AKT PROTAC degrader. MS15 inhibits the AKT1, -2, and -3 activities, with IC₅₀ values of 798 nM, 90 nM, and 544 nM, respectively .

HY-19934

Pifusertib TAS-117	Akt Apoptosis Autophagy	Cancer
Pifusertib (TAS-117) is a potent, selective, orally active allosteric Akt inhibitor (with IC₅₀s of 4.8, 1.6, and 44 nM for Akt1, 2, and 3, respectively). Pifusertib triggers anti-myeloma activities and enhances fatal endoplasmic reticulum (ER) stress induced by proteasome inhibition. Pifusertib induces apoptosis and autophagy .

HY-19934A

Pifusertib hydrochloride TAS-117 hydrochloride	Akt Apoptosis Autophagy	Cancer
Pifusertib (TAS-117) hydrochloride is a potent, selective, orally active allosteric Akt inhibitor (with IC₅₀s of 4.8, 1.6, and 44 nM for Akt1, 2, and 3, respectively). Pifusertib hydrochloride triggers anti-myeloma activities and enhances fatal endoplasmic reticulum (ER) stress induced by proteasome inhibition. Pifusertib hydrochloride induces apoptosis and autophagy .

HY-145670

cis,trans-Germacrone	Akt MDM-2/p53	Cancer
cis,trans-Germacrone is a isomer of Germacrone (HY-N0440). Germacrone exhibits a wide range of antitumor, antioxidant and anti-inflammatory effects. Germacrone inhibits lung cancer cell proliferation and alters the Akt/MDM2/p53. Germacrone also arrests cell cycle at G1/S phase .

HY-N0314R

Pectolinarin (Standard)	Interleukin Related Prostaglandin Receptor Apoptosis	Inflammation/Immunology
Pectolinarin (Standard) is the analytical standard of Pectolinarin. This product is intended for research and analytical applications. Pectolinarin possesses anti-inflammatory activity . Pectolinarin inhibits secretion of IL-6 and IL-8, as well as the production of PGE2 and NO. Pectolinarin suppresses cell proliferation and inflammatory response and induces apoptosis via inactivation of the PI3K/Akt pathway .

HY-141807

MS21	PROTACs Akt	Cancer
MS21 is an effective AKT PROTAC degrader. MS21 can inhibit mutations in the PI3K/PTEN pathway, suppress the proliferation and induce cell cycle arrest of tumor cells. MS21 has anti-tumor activity. (Pink: AKT ligand-2 (HY-48682); Black: Linker (HY-W014125); Blue: (S,R,S)-AHPC (HY-125845)) .

HY-15186

Ipatasertib 40+ Cited Publications GDC-0068; RG7440	Organoid Akt Apoptosis	Cancer
Ipatasertib (GDC-0068) is an orally active, highly selective and ATP-competitive pan-Akt inhibitor with IC₅₀ values of 5, 18, 8 nM for *Akt1/2/3, respectively. Ipatasertib synchronously activates FoxO3a and NF-κB through inhibition of Akt* leading to p53-independent activation of PUMA. Ipatasertib also induces apoptosis in cancer cells and inhibits tumor growth in xenograft mouse models ^[2].

HY-15186C

Ipatasertib tosylate GDC-0068 tosylate; RG7440 tosylate	Organoid Akt Apoptosis	Cancer
Ipatasertib (GDC-0068) tosylate is an orally active, highly selective and ATP-competitive pan-Akt inhibitor with IC₅₀ values of 5, 18, 8 nM for *Akt1/2/3, respectively. Ipatasertib tosylate synchronously activates FoxO3a and NF-κB through inhibition of Akt* leading to p53-independent activation of PUMA. Ipatasertib tosylate also induces apoptosis in cancer cells and inhibits tumor growth in xenograft mouse models ^[2].

HY-P5910

Azurin p28 peptide	MDM-2/p53 Apoptosis	Cancer
Azurin p28 peptide is a tumor-penetrated antitumor peptide. Azurin p28 peptide redues proteasomal degradation of p53 through formation of a p28: p53 complex. Azurin p28 peptide induces apoptosis or cell cycle arrest. Azurin p28 peptide inhibits p53-positive tumor growths. Azurin p28 peptide shows antiangiogenic effect by inhibiting phosphorylation of VEGFR-2, FAK and Akt .

HY-P5910A

Azurin p28 peptide TFA	MDM-2/p53 Apoptosis	Cancer
Azurin p28 peptide TFA is a tumor-penetrated antitumor peptide. Azurin p28 peptide TFA redues proteasomal degradation of p53 through formation of a p28: p53 complex. Azurin p28 peptide TFA induces apoptosis or cell cycle arrest. Azurin p28 peptide TFA inhibits p53-positive tumor growths. Azurin p28 peptide TFA shows antiangiogenic effect by inhibiting phosphorylation of VEGFR-2, FAK and Akt .

HY-134903

(32-Carbonyl)-RMC-5552	mTOR	Cancer
(32-Carbonyl)-RMC-5552 is a potent mTOR inhibitor. (32-Carbonyl)-RMC-5552 inhibits mTORC1 and mTORC2 substrate (p-P70S6K-(T389), p-4E-BP1-(T37/36), AND p-AKT1/2/3-(S473)) phosphorylation with pIC₅₀s of > 9, >9 and between 8 and 9, respectively (patent WO2019212990A1, example 2) .

HY-N0226

Epiberberine	Cholinesterase (ChE) Beta-secretase	Neurological Disease Metabolic Disease
Epiberberine is an alkaloid isolated from Coptis chinensis, acts as a potent AChE and BChE inhibitor, and a non-competitive BACE1 inhibitor, with IC₅₀s of 1.07, 6.03 and 8.55 μM, respectively. Epiberberine has antioxidant activity, with peroxynitrite ONOO ^- scavenging effect (IC₅₀, 16.83 μM), and can be used for the research of Alzheimer disease . Epiberberine inhibits the early stage of differentiation of 3T3-L1 preadipocytes, downregulates the Raf/MEK1/2/ERK1/2 and AMPKα/Akt pathways . Epiberberinecan be used for the research of diabetic disease .

HY-B1065

Aceglutamide α-N-Acetyl-L-glutamINe; N2-AcetylglutamINe	Keap1-Nrf2 Akt ASK1 Apoptosis	Neurological Disease
Aceglutamide (α-N-Acetyl-L-glutamine; N2-Acetylglutamine) is a neuroprotectant that can penetrate the blood-brain barrier. Aceglutamide can enhance the antioxidant systems of glutathione (GSH), thioredoxin (Trx) and *Nrf2. Aceglutamide also inhibits ASK1* and TRAF1, activates the *Akt/Bcl-2* anti-apoptotic pathway, enhances the activity of antioxidant enzymes and reduces oxidative damage. Aceglutamide can improve neurological deficits after cerebral ischemia, reduce infarct volume, and inhibit neuronal apoptosis, especially substantia nigra dopaminergic neurons. Aceglutamide can reduce cerebral ischemia/reperfusion injury, improve motor dysfunction, and is used in ischemic stroke-related research ^[2].

HY-N0226A

Epiberberine chloride 4 Publications Verification	Cholinesterase (ChE) Beta-secretase Reactive Oxygen Species	Neurological Disease Metabolic Disease
Epiberberine chloride is an alkaloid isolated from Coptis chinensis, acts as a potent AChE and BChE inhibitor, and a non-competitive BACE1 inhibitor, with IC₅₀s of 1.07, 6.03 and 8.55 μM, respectively. Epiberberine chloride has antioxidant activity, with peroxynitrite ONOO ^- scavenging effect (IC₅₀, 16.83 μM), and may protect against Alzheimer disease . Epiberberine chloride inhibits the early stage of differentiation of 3T3-L1 preadipocytes, downregulates the Raf/MEK1/2/ERK1/2 and AMPKα/Akt pathways . Epiberberine has the potential effect in the research of diabetic disease .

HY-B1065R

Aceglutamide (Standard) α-N-Acetyl-L-glutamINe (Standard); N2-AcetylglutamINe (Standard)	Keap1-Nrf2 Akt ASK1 Apoptosis	Neurological Disease
Aceglutamide (α-N-Acetyl-L-glutamine; N2-Acetylglutamine) (Standard) is the analytical standard of Aceglutamide (HY-B1065). This product is intended for research and analytical applications. Aceglutamide (α-N-Acetyl-L-glutamine; N2-Acetylglutamine) is a neuroprotectant that can penetrate the blood-brain barrier. Aceglutamide can enhance the antioxidant systems of glutathione (GSH), thioredoxin (Trx) and *Nrf2. Aceglutamide also inhibits ASK1* and TRAF1, activates the *Akt/Bcl-2* anti-apoptotic pathway, enhances the activity of antioxidant enzymes and reduces oxidative damage. Aceglutamide can improve neurological deficits after cerebral ischemia, reduce infarct volume, and inhibit neuronal apoptosis, especially substantia nigra dopaminergic neurons. Aceglutamide can reduce cerebral ischemia/reperfusion injury, improve motor dysfunction, and is used in ischemic stroke-related research ^[2].

Cat. No.	Product Name

HY-L077

Anti-Pancreatic Cancer Compound Library	3,366 compounds
Pancreatic cancer is a devastating disease with a low overall survival rate. Chemotherapy is the most common treatment for patients presenting with advanced pancreatic cancer. More recently, the era of targeted therapies has generated a lot of interest in discovering better approaches for patients with pancreatic cancer. Commonly mutated genes in pancreatic cancer include K-ras (in 74-100% of cases), p16INK4a (up to 98%), p53 (43 to 76%), DPC4 (about 50%), HER-2/neu (in about 65%) and FHIT (found in 70% of cases). Other genes involved are notch1, Akt-2, BRCA2 and COX-2. These proteins are important targets of target therapies for pancreatic cancer. MCE offers a unique collection of 3,366 compounds with identified and potential anti- pancreatic cancer activity. These compounds target K-Ras, p53, HER2, Notch, AKT, etc. MCE anti-pancreatic cancer compound library is a useful tool for anti-pancreatic cancer drugs screening and other related research.

Anti-Pancreatic Cancer Compound Library

3,366 compounds

Pancreatic cancer is a devastating disease with a low overall survival rate. Chemotherapy is the most common treatment for patients presenting with advanced pancreatic cancer. More recently, the era of targeted therapies has generated a lot of interest in discovering better approaches for patients with pancreatic cancer. Commonly mutated genes in pancreatic cancer include K-ras (in 74-100% of cases), p16INK4a (up to 98%), p53 (43 to 76%), DPC4 (about 50%), HER-2/neu (in about 65%) and FHIT (found in 70% of cases). Other genes involved are notch1, Akt-2, BRCA2 and COX-2. These proteins are important targets of target therapies for pancreatic cancer.

MCE offers a unique collection of 3,366 compounds with identified and potential anti- pancreatic cancer activity. These compounds target K-Ras, p53, HER2, Notch, AKT, etc. MCE anti-pancreatic cancer compound library is a useful tool for anti-pancreatic cancer drugs screening and other related research.

Cat. No.	Product Name	Target	Research Area